Duodopa (Parkinsons Disease) Market Trend & Analysis Report 2022: Radiant Insights, Inc
Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly.
Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain.
GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/duodopa-parkinson-s-disease-forecast-and-market-analysis-to-2022
Developed by AbbVie, Duodopa is a gel composed of carbidopa/levodopa and administered via a pump into the intestine, where the drug is absorbed. It is approved for patients with advanced Parkinson's disease with motor fluctuations.
Continual infusion provides steady state serum drug levels, while the patient experiences relative freedom from oral medications and optimal control of motor symptoms, including ON-OFF and dyskinesias.
Scope
- Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Duodopa including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Duodopa for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain,...